Pharmaceutical company Eisai has launched Uritos tablets (imidafenacin) to treat overactive bladder (OAB), in Thailand.

OAB is a urological condition, where the patient will have a frequent, sudden urge to urinate. It is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

KYORIN Pharmaceutical, a subsidiary of Kyorin Holdings, has given Eisai the exclusive rights to develop and market the therapeutic agent in China, India, Sri Lanka and ASEAN countries in 2009.

Uritos is an anti-cholinergic agent that exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with OAB, Eisai said in a statement.

The most common side effects associated with the consumption of Uritos are thirst and constipation.

“According to the clinical guidelines for overactive bladder in Japan, the prevalence of OAB in the country ranges from 5% to 20%.”

Previous studies have shown that people suffering from brain or spinal cord related diseases such as stroke or Parkinson’s disease, as well as enlargement of the prostate are at high risk of OAB.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the clinical guidelines for overactive bladder in Japan, the prevalence of OAB in the country ranges from 5% to 20%.

Although the prevalence of OAB in Asia is unknown, reports suggest that 29.9% of men and 34.7% of women older than 18 experienced some symptoms of OAB, many of whom did not receive appropriate treatment due to lack of disease awareness.

In a separate development, Eisai’s research subsidiary Morphotek has signed an exclusive licensing agreement with Eurofarma Laboratórios to develop and commercialise the monoclonal antibody farletuzumab as a potential anticancer agent in Latin America.

Image: Eisai head office in Tokyo. Photo: courtesy of KW.